



## Klinik für Urologie: Erfasste Publikationen aus 2020

ID: 280488

[Bladder cancer - complications related to urinary diversion].

**Aktuelle Urol** 2020; 51(5): 456-462; Impact Factor=0.658; Impact Factor 2024=0.4; Typ=Journal Article;English Abstract;

Pfister D, **Niegisch G**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280480

[Complication management for TUR of the bladder].

**Aktuelle Urol** 2020; 51(5): 450-455; Impact Factor=0.658; Impact Factor 2024=0.4; Typ=Journal Article;English Abstract;

**Mally D**, Paffenholz P

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 279626

[Kein Titel angegeben]

**Aktuelle Urol** 2020; 51(1): 71-80; Impact Factor=0.658; Impact Factor 2024=0.4; Typ=Journal Article;

**Albers P**, **Hörtl W**, **Heidenreich A**, **Aharinejad S**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280497

[Prostate cancer: surgical complications].

**Aktuelle Urol** 2020; 51(5): 469-474; Impact Factor=0.658; Impact Factor 2024=0.4; Typ=Journal Article;English Abstract;

Haidl F, **Al-Monajjed R**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280479

[Radical nephrectomy and partial nephrectomy].

**Aktuelle Urol** 2020; 51(5): 441-449; Impact Factor=0.658; Impact Factor 2024=0.4; Typ=Journal Article;English Abstract;

Eich C, **Giessing M**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280498

[Retroperitoneal lymph node dissection in testicular germ cell tumours: indications, complications and special cases].

**Aktuelle Urol** 2020; 51(5): 475-481; Impact Factor=0.658; Impact Factor 2024=0.4; Typ=Journal Article;

John P, **Albers P**, **Hiester A**, Heidenreich A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280392

[Systemic therapy for metastatic urothelial carcinoma - Current status and what comes after checkpoint inhibitors?]

**Aktuelle Urol** 2020; 51(4): 371-376; Impact Factor=0.658; Impact Factor 2024=0.4; Typ=Journal Article;English Abstract;

**Grunewald CM, Hiester A, Niegisch G**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280208

Knockdown of Myoferlin Suppresses Migration and Invasion in Clear-Cell Renal-Cell Carcinoma.

**Anticancer Res** 2020; 40(6): 3119-3128; Impact Factor=2.48; Impact Factor 2024=1.7; Typ=Journal Article;

Cox A, Zhao C, Tolkach Y, **Nettersheim D**, Schmidt D, Kristiansen G, Mueller SC, Ritter M, Hauser S, Ellinger J

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 279919

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.

**BMC Cancer** 2020; 20(1): 230; Impact Factor=4.43; Impact Factor 2024=3.4; Typ=Journal Article;

Morsch R, Rose M, Maurer A, Cassataro MA, Braunschweig T, Knüchel R, Vögeli TA, Ecke T, Eckstein M, Weyerer V, Esposito I, Ackermann M, **Niegisch G**, Gaisa NT, German Study Group of Bladder Cancer (DFBK e.V.)

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 278925

CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms.

**Br J Cancer** 2020; 123(3): 378-391; Impact Factor=7.64; Impact Factor 2024=6.8; Typ=Journal Article;

**Skowron MA, Vermeulen M, Winkelhausen A, Becker TK**, Bremmer F, Petzsch P, Schönberger S, Calaminus G, Köhrer K, **Albers P, Nettersheim D**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 279779

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?

**Br J Cancer** 2020; 122(4): 453-454; Impact Factor=7.64; Impact Factor 2024=6.8; Typ=Editorial;

**Niegisch G**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 348542

A Canadian approach to the regionalization of testis cancer: A review.

**Can Urol Assoc J** 2020; 14(10): 346-351; Impact Factor=1.862; Impact Factor 2024=2.0; Typ=Journal Article;Review;

Nason GJ, Wood LA, Huddart RA, **Albers P**, Rendon RA, Einhorn LH, Nichols CR, Kollmannsberger C, Anson-Cartwright L, Sweet J, Warde P, Jewett MAS, Chung P, Bedard PL, Hansen AR, Hamilton RJ

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 348648

Controversies in the management of clinical stage 1 testis cancer.

**Can Urol Assoc J** 2020; 14(11): E537-E542; Impact Factor=1.862; Impact Factor 2024=2.0;

Typ=Journal Article;

Nason GJ, Chung P, Warde P, Huddart R, **Albers P**, Kollmannsberger C, Booth CM, Hansen AR, Bedard PL, Einhorn L, Nichols C, Rendon RA, Wood LA, Jewett MAS, Hamilton RJ

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 216088

Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with

Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology.

**Cancers** 2020; 12(3): ; Impact Factor=6.639; Impact Factor 2024=4.4; Typ=Journal Article; Calaminus G, Schneider DT, von Schweinitz D, Jürgens H, Infed N, Schönberger S, Olson TA, **Albers P**, Vokuhl C, Stein R, Looijenga L, Sehouli J, Metzelder M, Claviez A, Dworzak M, Eggert A, Fröhlich B, Gerber NU, Kratz CP, Faber J, Klingebiel T, Harms D, Göbel U  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280150

Regulates Transcription and the Epigenetic Landscape via POLE and DMAP1 while Deficiency or Pharmacological Inhibition Sensitizes Germ Cell Tumor Cells to ATR Inhibition.

**Cancers (Basel)** 2020; 12(4): ; Impact Factor=6.639; Impact Factor 2024=4.4; Typ=Journal Article; **Kurz L**, **Miklyeva A**, **Skowron MA**, Overbeck N, Poschmann G, **Becker T**, **Eul K**, Kurz T, Schönberger S, Calaminus G, Stühler K, Dykhuizen E, **Albers P**, **Nettersheim D**  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 383618

A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients' Omics Signatures.

**Cancers (Basel)** 2020; 12(12): ; Impact Factor=6.639; Impact Factor 2024=4.4; Typ=Journal Article; Mokou M, Lygirou V, Angeliodaki I, Paschalidis N, Strogilos R, Frantzi M, Latosinska A, Bamias A, **Hoffmann MJ**, Mischak H, Vlahou A  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 279924

Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1.

**Cancers (Basel)** 2020; 12(2): ; Impact Factor=6.639; Impact Factor 2024=4.4; Typ=Journal Article; Wang C, Hamacher A, Petzsch P, Köhrer K, **Niegisch G**, **Hoffmann MJ**, **Schulz WA**, Kassack MU  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 348598

Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors.

**Cancers (Basel)** 2020; 12(10): ; Impact Factor=6.639; Impact Factor 2024=4.4; Typ=Journal Article; Lobo J, Guimarães-Teixeira C, Barros-Silva D, Miranda-Gonçalves V, Camilo V, Guimarães R, Cantante M, Braga I, Maurício J, Oing C, Honecker F, **Nettersheim D**, Looijenga LH, Henrique R, Jerónimo C  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280151

Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines.

**Cancers (Basel)** 2020; 12(4): ; Impact Factor=6.639; Impact Factor 2024=4.4; Typ=Journal Article; **Lang A**, **Whongsiri P**, **Yilmaz M**, Lautwein T, Petzsch P, Greife A, Günes C, Köhrer K, **Niegisch G**, **Hoffmann M**, **Schulz WA**  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280219

Targeting EpCAM by a Bispecific Trifunctional Antibody Exerts Profound Cytotoxic Efficacy in Germ Cell Tumor Cell Lines.

**Cancers (Basel)** 2020; 12(5): ; Impact Factor=6.639; Impact Factor 2024=4.4; Typ=Journal Article; Schönberger S, Kraft D, **Nettersheim D**, Schorle H, Casati A, Craveiro RB, Mohseni MM, Calaminus G,

Dilloo D

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 383635

Filamin A Orchestrates Cytoskeletal Structure, Cell Migration and Stem Cell Characteristics in Human Seminoma TCam-2 Cells.

**Cells** 2020; 9(12): ; Impact Factor=6.6; Impact Factor 2024=5.2; Typ=Journal Article;

Welter H, Herrmann C, Fröhlich T, Flenkenthaler F, Eubler K, Schorle H, **Nettersheim D**, Mayerhofer A, Müller-Taubenberger A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 348576

Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study.

**Clin Genitourin Cancer** 2020; 18(5): e543-e556; Impact Factor=2.872; Impact Factor 2024=2.7; Typ=Journal Article;

Bandini M, Pederzoli F, Madison R, Briganti A, Ross JS, **Niegisch G**, Yu EY, Bamias A, Agarwal N, Sridhar SS, Rosenberg JE, Bellmunt J, Pal SK, Galsky MD, Lucianò R, Gallina A, Salonia A, Montorsi F, Ali SM, Chung JH, Necchi A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 279892

Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells.

**Cytometry B Clin Cytom** 2020; 98(4): 355-367; Impact Factor=3.058; Impact Factor 2024=2.7; Typ=Journal Article;

**Nini A**, **Hoffmann MJ**, Lampignano R, **Große Siemer R**, van Dalum G, Szarvas T, Cotarello CL, **Schulz WA**, Niederacher D, Neubauer H, Stoecklein NH, **Niegisch G**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 348700

Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients.

**Diagnostics (Basel)** 2020; 10(11): ; Impact Factor=3.706; Impact Factor 2024=3.3; Typ=Journal Article; Olah C, Tschirdewahn S, **Hoffmann MJ**, Krafft U, Hadaschik B, Nyirady P, Szendrői A, Módos O, Csizmarik A, Kovalszky I, Reis H, Szarvas T

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280144

Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3).

**Eur J Cancer** 2020; 132(): 127-135; Impact Factor=9.162; Impact Factor 2024=7.1; Typ=Journal Article;

Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser C, Hermanns T, Aparicio J, Heinzlbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, **Lorch A**, **Fingerhut A**, Gayer F, Bremmer F, Giannatempo P, Necchi A, Aurilio G, Casadei C, Tran B, Dieckmann KP, Brito M, Ruf C, Oing C, Bokemeyer C

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280519

Advanced diffusion weighted imaging of the prostate: Comparison of readout-segmented multi-shot, parallel-transmit and single-shot echo-planar imaging.

**Eur J Radiol** 2020; 130(): 109161; Impact Factor=3.528; Impact Factor 2024=3.3; Typ=Journal Article;

Klingebiel M, Ullrich T, Quentin M, Bonekamp D, Aissa J, **Mally D**, **Arsov C**, **Albers P**, Antoch G,

Schimmöller L

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 348834

Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study.

**Eur Radiol** 2020; 30(11): 6042-6051; Impact Factor=5.315; Impact Factor 2024=4.7; Typ=Journal Article;

Ullrich T, **Arsov C**, Quentin M, Mones F, Westphalen AC, **Mally D**, **Hiester A**, **Albers P**, Antoch G, Schimmöller L

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 217838

Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.

**Eur Urol** 2020; 78(6): 779-782; Impact Factor=20.096; Impact Factor 2024=25.2; Typ=Journal Article;

Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, **Hiester A**, **Nini A**, **Albers P**, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Motttrie A, Karakiewicz PI, Montorsi F, Briganti A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 217841

Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.

**Eur Urol** 2020; 78(5): 661-669; Impact Factor=20.096; Impact Factor 2024=25.2; Typ=Journal Article;

Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, **Hiester A**, **Nini A**, **Albers P**, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Motttrie A, Karakiewicz PI, Montorsi F, Briganti A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 279764

The Complex and Nuanced Care for Early-stage Testicular Cancer: Lessons from the European Association of Urology and American Urological Association Testis Cancer Guidelines.

**Eur Urol** 2020; 77(2): 139-141; Impact Factor=20.096; Impact Factor 2024=25.2; Typ=Editorial;

Bagrodia A, Pierorazio P, Singla N, **Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 279674

Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database.

**Eur Urol Oncol** 2020; 3(1): 94-101; Impact Factor=7.479; Impact Factor 2024=9.3; Typ=Journal Article;

Moschini M, Xylinas E, Zamboni S, Mattei A, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A, **RISC**

**Investigators**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 279294

Unique and redundant roles of SOX2 and SOX17 in regulating the germ cell tumor fate.

**Int J Cancer** 2020; 146(6): 1592-1605; Impact Factor=7.396; Impact Factor 2024=4.7; Typ=Journal

Article;Research Support, Non-U.S. Gov't;

Jostes SV, Fellermeier M, Arévalo L, Merges GE, Kristiansen G, **Nettersheim D**, Schorle H  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280341

In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi).

**Int J Mol Sci** 2020; 21(13): ; Impact Factor=5.923; Impact Factor 2024=4.9; Typ=Journal Article;  
Friedrich A, Assmann AS, Schumacher L, Stuijvenberg JV, Kassack MU, **Schulz WA**, Roos WP, Hansen FK, Pflieger M, Kurz T, Fritz G  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 383623

Many Different LINE-1 Retroelements Are Activated in Bladder Cancer.

**Int J Mol Sci** 2020; 21(24): ; Impact Factor=5.923; Impact Factor 2024=4.9; Typ=Journal Article;  
**Whongsiri P**, Goering W, Lautwein T, **Hader C**, **Niegisch G**, Köhrer K, **Hoffmann MJ**, **Schulz WA**  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 383630

Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies.

**J Pers Med** 2020; 10(4): ; Impact Factor=4.945; Impact Factor 2024=n.a.; Typ=Journal Article;  
Osses DF, **Arsov C**, Schimmöller L, Schoots IG, van Leenders GJLH, Esposito I, Remmers S, **Albers P**, Roobol MJ  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280099

Editorial Comment.

**J Urol** 2020; 203(5): 955; Impact Factor=7.45; Impact Factor 2024=7.5; Typ=Journal Article;Comment;  
**Hiester A**  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 382237

Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.

**J Urol** 2020; 204(6): 1173-1179; Impact Factor=7.45; Impact Factor 2024=7.5; Typ=Journal Article;Research Support, N.I.H., Extramural;  
Sonpavde G, Manitz J, Gao C, Tayama D, Kaiser C, Hennessy D, Makari D, Gupta A, Abdullah SE, **Niegisch G**, Rosenberg JE, Bajorin DF, Grivas P, Apolo AB, Dreicer R, Hahn NM, Galsky MD, Necchi A, Srinivas S, Powles T, Choueiri TK, Pond GR  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 382238

Robotic Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer.

**J Urol** 2020; 204(6): 1242-1248; Impact Factor=7.45; Impact Factor 2024=7.5; Typ=Journal Article;  
**Hiester A**, **Nini A**, **Arsov C**, **Buddensieck C**, **Albers P**  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 212466

Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of 68Ga-PSMA and 11C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections.

**J Urol** 2020; 204(2): 296-302; Impact Factor=7.45; Impact Factor 2024=7.5; Typ=Journal Article; Fossati N, Scarcella S, Gandaglia G, Suardi N, Robesti D, Boeri L, Karnes RJ, Heidenreich A, Pfister D, Kretschmer A, Buchner A, Stief C, Battaglia A, Joniau S, Van Poppel H, Osmonov D, Juenemann KP, Shariat S, **Hiester A**, **Nini A**, **Albers P**, Tilki D, Graefen M, Gill IS, Mottrie A, Galosi AB, Montorsi F, Briganti A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 425957

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.

**Lancet Oncol** 2020; 21(12): 1574-1588; Impact Factor=41.316; Impact Factor 2024=35.9; Typ=Clinical Trial, Phase III;Comparative Study;Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, Non-U.S. Gov't;

Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J, DANUBE study investigators

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 415648

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.

**N Engl J Med** 2020; 383(11): 1040-1049; Impact Factor=91.245; Impact Factor 2024=78.5; Typ=Clinical Trial, Phase III;Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, Non-U.S. Gov't;

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR, **ARAMIS Investigators**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280202

Can you trust the Prostate Imaging Reporting and Data System (PI-RADS) in special cases?

**Rofo** 2020; 192(6): 580-583; Impact Factor=2.452; Impact Factor 2024=1.7; Typ=Journal Article;

Valentin B, Blondin D, Ullrich T, **Arsov C**, Ackermann M, **Antoch G**, Schimmöller L

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280047

Value of Dynamic Contrast-Enhanced (DCE) MR Imaging in Peripheral Lesions in PI-RADS-4 Patients.

**Rofo** 2020; 192(5): 441-447; Impact Factor=2.452; Impact Factor 2024=1.7; Typ=Journal Article;

Ullrich T, Quentin M, **Arsov C**, Laqua N, Abrar D, **Hiester A**, **Albers P**, Antoch G, Schimmöller L

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280486

Basic Hallmarks of Urothelial Cancer Unleashed in Primary Uroepithelium by Interference with the Epigenetic Master Regulator ODC1.

**Sci Rep** 2020; 10(1): 3808; Impact Factor=4.379; Impact Factor 2024=3.9; Typ=Journal Article;Research Support, Non-U.S. Gov't;

Ericksen L, Seifert HH, **Schulz WA**, **Hoffmann MJ**, **Niegisch G**, Araúzo-Bravo MJ, Bendhack ML, Poyet C, Hermanns T, Beermann A, Hassan M, Theis L, Mahmood W, Santourlidis S

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 383628

Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient

survival.

**Urol Oncol** 2020; 38(12): 934.e1-934.e9; Impact Factor=3.498; Impact Factor 2024=2.3; Typ=Journal Article;

**Grunewald CM**, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Sternberg CN, Bellmunt J, Baniel J, **Niegisch G**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 280346

The contrasting roles of Dysferlin during tumor progression in renal cell carcinoma.

**Urol Oncol** 2020; 38(8): 687.e1-687.e11; Impact Factor=3.498; Impact Factor 2024=2.3; Typ=Journal Article;

Cox A, Zhao C, Tolkach Y, **Nettersheim D**, Schmidt D, Kristiansen G, Hauser S, Müller SC, Ritter M, Ellinger J

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 279412

[Changes in the treatment of metastatic prostate cancer-new data and open questions].

**Urologe A** 2020; 59(3): 307-317; Impact Factor=0.639; Impact Factor 2024=n.a.; Typ=Journal Article;

**Albers P**, Bögemann M, Machtens S, Merseburger AS, Schostak M, Steuber T, Wülfing C, De Santis M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 279908

[Report from the 9th symposium of the German Association for Bladder Cancer Research].

**Urologe A** 2020; 59(6): 731-732; Impact Factor=0.639; Impact Factor 2024=n.a.; Typ=Journal Article;

**Schulz WA**, **Hoffmann MJ**, Niegisch G, Fussel S, Nawroth R

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 348852

[Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].

**Urologe A** 2020; 59(7): 804-809; Impact Factor=0.639; Impact Factor 2024=n.a.; Typ=Journal Article;Review;

Zschäbitz S, **Niegisch G**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 218603

[The 27th annual meeting of the working group kidney transplantation of the German Society for Urology : November 21-24, 2019 in Halle (Saale)].

**Urologe A** 2020; 59(1): 84-86; Impact Factor=0.639; Impact Factor 2024=n.a.; Typ=Journal Article;

Weigand K, Friedersdorff F, Apel H, Stöckle M, Putz J, Dreikorn K, **Giessing M**, Fornara P

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 210437

Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases.

**World J Urol** 2020; 38(8): 1959-1968; Impact Factor=4.226; Impact Factor 2024=2.9; Typ=Journal Article;

Gontero P, Pisano F, Palou J, Joniau S, Albersen M, Colombo R, Briganti A, Pellucchi F, Faba OR, van Rhijn BW, van de Putte EF, Babjuk M, Fritsche HM, Mayr R, **Albers P**, **Niegisch G**, Anract J, Masson-Lecomte A, De la Taille A, Roupret M, Peyronnet B, Cai T, Witjes AJ, Bruins M, Baniel J, Mano R, Lapini A, Sessa F, Irani J, Brausi M, Stenzl A, Karnes JR, Scherr D, O'Malley P, Taylor B, Shariat SF, Black P, Abdi H, Matveev VB, Samuseva O, Parekh D, Gonzalgo M, Vetterlein MW, Aziz A, Fisch M, Catto J,

Pang KH, Xylinas E, Rink M, Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

